HENRIETTA, N.Y., June 07, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (“DSS” or the “Company”) (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically acquiring and developing assets to enrich the value of its shareholders through calculated IPO spinoffs and a parametric share distribution strategy, today announced Global BioLife, Inc. (“Global BioLife”), a division of the Company’s wholly owned subsidiary Impact BioMedical, was granted a patent (No. 2020119933780) from the China National Intellectual Property Administration (“CNIPA”) for 3F™, a Functional Fragrance Formulation (3F™) technology that is effective as a mosquito repellant through a fragrant compound derived from botanical oils. This complements the corresponding U.S. patent granted (U.S. 11,246,310)
DSS’s Impact BioMedical Receives China Patent for its Functional Fragrance Formulation Mosquito Repellant
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
